Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomized, controlled, open-label, platform trial
“In patients admitted to hospital with COVID-19, azithromycin did not improve survival or other prespecified clinical outcomes. Azithromycin use in patients admitted to hospital with COVID-19 should be restricted to patients in whom there is a clear antimicrobial indication.” (J. Harris: So, Z PAC doesn’t treat Covid.)
(A Spanish study that showed that a high viral load in an infected person caused the most spread and disease severity and onset was quicker, which is one explanation for why some individuals are so much sicker than other family members sick at the same time. The study showed infectivity occurred 5-7 days after exposure, but exposure to contacts with lower viral counts might take 12-14 days to produce infection. Most of what this study shows is about what you would expect, except that the presence of cough was not too important nor was AGE. Toggle the article and read the summary if you are interested. Spain has much better tracking and tracing ability than does the USA.)
(J. Harris: This is a readable article that is pretty close to being reliable. It points out that not everyone agrees with all of it; things are moving fast and some of the more reliable scientific studies take more time. Those studies are being done, however. )
1. GOOD NEWS: Vaccines are Curbing COVID: Data from Israel Show Drop in Infections (Nature) Good news from Israel. Researchers are seeing signs that COVID-19 vaccines are helping to curb infections and hospitalizations among older people, almost 6 weeks after shots were rolled out in that group. The country is the first to release data showing vaccines working in such a large group of people, following news two weeks ago that shots seemed to be reducing infections in vaccinated individuals. Close to 90% of people aged 60 and older in the country have received their first dose of Pfizer’s 2-dose vaccine so far. Now, data collected by Israel’s Ministry of Health show that there was a 41% drop in confirmed COVID-19 infections in that age group, and a 31% drop in hospitalizations from mid-January to early February.
2. Intranasal Influenza Vaccine Spurs Strong Immune Response in Phase 1 Study An experimental single-dose, intranasal influenza vaccine was safe and produced a durable immune response when tested in a Phase 1 study published in the Journal of Clinical Investigation. The investigational vaccine, called Ad4-H5-VTN, is a recombinant, replicating adenovirus vaccine designed to spur antibodies to hemagglutinin, a protein found on the surface of influenza viruses that attaches to human cells. The participants who received the vaccine intranasally or via tonsillar swab showed significantly higher H5-specific neutralizing antibody levels compared to the group receiving the vaccine capsule orally. (NIH, 2/3/2021)
(J. Harris: Next we need to find a similar vaccine for Covd, and we probably will, with time.)
NO JOKES; LOOK AT THE VIDEO INSTEAD.
WATCH THIS 2 MIN. VIDEO THAT WILL MAKE YOUR DAY. Click here to see video
GIVE US YOUR FEEDBACK. CLICK ON “COMMENT” TO TELL US WHAT YOU THINK or use one of the alternative methods for providing feedback.